Bionano Genomics (NASDAQ:BNGO) Raised to Hold at Wall Street Zen

Bionano Genomics (NASDAQ:BNGO) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Bionano Genomics currently has a consensus rating of “Hold” and an average price target of $6.00.

Bionano Genomics Stock Performance

Shares of NASDAQ:BNGO opened at $1.66 on Friday. The firm has a 50 day moving average of $1.26 and a 200 day moving average of $1.22. The company has a quick ratio of 1.96, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $19.55 million, a price-to-earnings ratio of -0.55 and a beta of 1.65. Bionano Genomics has a 52 week low of $1.00 and a 52 week high of $2.23.

Bionano Genomics (NASDAQ:BNGO) last announced its earnings results on Monday, August 10th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.03. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%.The business had revenue of ($6.67) million for the quarter, compared to analysts’ expectations of $7.55 million. On average, sell-side analysts predict that Bionano Genomics will post -2.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bionano Genomics

An institutional investor recently bought a new stake in Bionano Genomics stock. GSA Capital Partners LLP purchased a new position in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 150,284 shares of the company’s stock, valued at approximately $170,000. GSA Capital Partners LLP owned 1.31% of Bionano Genomics as of its most recent filing with the Securities and Exchange Commission. 11.35% of the stock is currently owned by institutional investors.

About Bionano Genomics

Bionano Genomics, Inc is a life sciences company that develops genomic analysis technologies designed to identify structural variation and other genetic abnormalities that may be difficult to detect with conventional sequencing methods. The company’s platform is used in research, clinical, and pharmaceutical applications, including studies of cancer, inherited disease, and genome biology.

Its primary product is the Saphyr system, an optical genome mapping platform that analyzes long, fluorescently labeled DNA molecules as they pass through nanochannel arrays.